Patients across all indications benefit from the rapid response of Enbrel® treatment1-17
Early clinical improvements observed1-3
Juvenile Idiopathic Arthritis
Therapeutic improvements observed as early as 4 weeks4-7
Improvements in disease activity and symptoms across all stages of the disease as early as 2 weeks8-11
Clinical improvements observed as early as 2 weeks12-13
Symptom relief as early as 2 weeks14-17
AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis.
Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ENB-IND-0814 August 2022
Clinical improvements as early as
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.